Covalent Modification of Thr302 in Cytochrome P450 2B1 by the Mechanism-Based Inactivator 4-tert-Butylphenylacetylene
Authors:
- Haoming ZhangHZHaoming Zhang
- Monica JushchyshynMJMonica Jushchyshyn
- Paul F. HollenbergPHPaul F. Hollenberg
- 1 June 2010
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 333 (3) , 663-669
Abstract
The mechanism of inactivation of cytochrome P450 2B1 (CYP2B1) by 4-tert-butylphenylacetylene (BPA) has been characterized previously to be caused by the covalent binding of a reactive intermediate to the apoprotein rather than heme destruction (J Pharmacol Exp Ther331:392–403, 2009). The identification of a BPA-glutathione conjugate and the increase in the mass of the BPA-adducted apoprotein have indicated that the mass of adduct is 174 Da, equivalent to the mass of BPA plus one oxygen atom. To identify the adducted residue, BPA-inactivated CYP2B1 was digested with trypsin, and the digest was then analyzed by using capillary liquid chromatography with a LTQ linear ion trap mass spectrometer as the detector. A mass shift of 174 Da was used for a SEQUEST database search. The tandem mass spectrometry fragmentation of the modified peptide and the identity of modified residue were determined. The results revealed a mass increase of 174 Da for the peptide sequence 296FFAGTSSTTLR308 in the I-helix of CYP2B1 and that the site of adduction formation is Thr302. Homology modeling and ligand docking studies showed that BPA binds in close proximity to both the heme iron and Thr302 with the distances being 2.96 and 3.42 Å, respectively. The identification of Thr302 in the CYP2B1 active site as the site of covalent modification leading to inactivation by BPA supports previous hypotheses that this conserved Thr residue may play a crucial role for various functions in P450s.Keywords
This publication has 36 references indexed in Scilit:
- tert-Butylphenylacetylene Is a Potent Mechanism-Based Inactivator of Cytochrome P450 2B4: Inhibition of Cytochrome P450 Catalysis by Steric HindranceMolecular Pharmacology, 2009
- Mechanism-Based Inactivation of CYP2B1 and Its F-Helix Mutant by Two tert-Butyl Acetylenic Compounds: Covalent Modification of Prosthetic Heme Versus ApoproteinThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Modification of Serine 360 by a Reactive Intermediate of 17-α-Ethynylestradiol Results in Mechanism-Based Inactivation of Cytochrome P450s 2B1 and 2B6Chemical Research in Toxicology, 2008
- Time-Dependent Inactivation of P450 3A4 by Raloxifene: Identification of Cys239 as the Site of Apoprotein Alkylation1Chemical Research in Toxicology, 2007
- Fluorescent Photoaffinity Labeling of Cytochrome P450 3A4 by Lapachenole: Identification of Modification Sites by Mass SpectrometryBiochemistry, 2005
- Secobarbital-mediated Inactivation of Cytochrome P450 2B1 and Its Active Site MutantsJournal of Biological Chemistry, 1996
- Identification of Active-Site Peptides from 3H-Labeled 2-Ethynylnaphthalene-Inactivated P450 2B1 and 2B4 Using Amino Acid Sequencing and Mass SpectrometryBiochemistry, 1994
- Mechanism-based inactivation of cytochrome P450 2B1 by 2-ethynylnaphthalene: Identification of an active-site peptideChemical Research in Toxicology, 1993
- Site-directed mutagenesis of cytochrome P450s CYP2A1 and CYP2A2: influence of the distal helix on the kinetics of testosterone hydroxylationBiochemistry, 1992
- The importance of threonine‐301 from cytochromes P‐450 (laurate (ω‐1)‐hydroxylase and testosterone 16α‐hydroxylase) in substrate binding as demonstrated by site‐directed mutagenesisFEBS Letters, 1988